帕西瑞肽
| CAS号 | 396091-73-9 | 货号 | BCP28075 |
| 中文名 | 帕西瑞肽 | ||
| 英文名 | Pasireotide | ||
| 中文别名 | |||
| 英文别名 | SOM 230; SOM-230; SOM230; | ||
| 分子式 | C58H66N10O9 | 分子量 | 1047.23 |
| 生物活性 | Pasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. | ||
| 信号通路 | GPCR/G Protein | ||
| 靶 点 | Somatostatin Receptor | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！